Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Sees Large Increase in Short Interest

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) was the recipient of a significant growth in short interest in the month of October. As of October 15th, there was short interest totalling 40,500 shares, a growth of 163.0% from the September 30th total of 15,400 shares. Based on an average trading volume of 12,300 shares, the short-interest ratio is presently 3.3 days. Currently, 0.5% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on Cumberland Pharmaceuticals in a research report on Friday. They issued a “hold” rating for the company.

Cumberland Pharmaceuticals Stock Performance

CPIX stock traded down $0.02 during midday trading on Friday, hitting $1.22. The stock had a trading volume of 21,146 shares, compared to its average volume of 10,725. Cumberland Pharmaceuticals has a 52 week low of $1.19 and a 52 week high of $2.36. The company has a current ratio of 1.44, a quick ratio of 1.26 and a debt-to-equity ratio of 0.62. The stock has a 50-day simple moving average of $1.29 and a 200 day simple moving average of $1.44. The firm has a market capitalization of $17.31 million, a price-to-earnings ratio of -2.07 and a beta of 0.20.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.